Prognostic value of genomic alterations in invasive cervical squamous cell carcinoma of clinical stage IB detected by comparative genomic hybridization

Cancer Research

Volumn 59, Issue 14, 1999, Pages 3475-3479

  Dellas, Athanassios ^a   Torhorst, Joachim ^a   Jiang, Feng ^a   Proffitt, John ^b   Schultheiss, Elisabeth ^a   Holzgreve, Wolfgang ^a   Sauter, Guido ^a   Mihatsch, Michael J ^a   Moch, Holger ^a  

^a UNIVERSITY OF BASEL   (Switzerland)

^b ABBOTT LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; NUCLEAR PROTEIN;

ARTICLE; CANCER GROWTH; CANCER STAGING; CHROMOSOME; COMPARATIVE GENOMIC HYBRIDIZATION; CONTROLLED STUDY; DNA SEQUENCE; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE; GENE INACTIVATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INVASIVE CARCINOMA; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROGNOSIS; TUMOR SUPPRESSOR GENE; UTERINE CERVIX CARCINOMA;

CARCINOMA, SQUAMOUS CELL; CHROMOSOME ABERRATIONS; CHROMOSOMES, HUMAN; DNA, NEOPLASM; FEMALE; FOLLOW-UP STUDIES; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; LIFE TABLES; LYMPHATIC METASTASIS; MALE; NUCLEIC ACID HYBRIDIZATION; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; SURVIVAL ANALYSIS; TREATMENT OUTCOME; UTERINE CERVICAL NEOPLASMS;

EID: 0033565240     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Cervical Cancer, NIH Consensus Statement, Vol. 14, pp. 1-38. Bethesda, MD: NIH, 1996.
2. zur Hausen, H. Papillomavirus and p53. Nature (Lond.), 393: 217, 1998.
3. Larson, A. A., Kern, S., Curtiss, S., Gordon, R., Cavenee, W. K., and Hampton, G. M. High resolution analysis of chromosome 3p alterations in cervical carcinoma. Cancer Res., 57: 4082-4090, 1997.
4. Wistuba, I. I., Montellano, F. D., Milchgrub, S., Virmani, A. K., Behrens, C., Chen, H., Ahmadian, M., Nowak, J. A., Muller, C., Minna, J. D., and Gazdar, A. F. Deletions of chromosome 3p are frequent and early events in the pathogenesis of uterine cervical carcinoma. Cancer Res., 57: 3154-3158, 1997.
5. Heselmeyer, K., Schrock, E., du Manoir, S., Biegen, H., Shah, K., Steinbeck, R., Auer, G., and Ried, T. Gain of chromosome 3q defines the transition from severe dysplasia to invasive carcinoma of the uterine cervix. Proc. Natl. Acad. Sci. USA, 93: 479-484, 1996.
6. Heselmeyer, K., Macville, M., Schrock, E., Blegen, H., Hellstrom, A. C., Shah, K., Auer, G., and Ried, T. Advanced-stage cervical carcinomas are defined by a recurrent pattern of chromosomal aberrations revealing high genetic instability and a consistent gain of chromosome arm 3q. Genes Chromosomes Cancer, 19: 233-240, 1997.
7. Kallioniemi, A., Kallioniemi, O. P., Sudar, D., Rutovitz, D., Gray, J. W., Waldman, F., and Pinkel, D. Comparative genomic hybridization for molecular cytogenetic analysis of solid tumors. Science (Washington DC), 258: 818-821, 1992.
8. Pecorelli, S., Creasman, W., Petterson, F., Benedet, J., and Shepherd, J. FIGO Annual Report on the Results of Treatment in Gynaecological Cancer. J. Epidemiol. Statistics, 3: 1-168, 1998.
9. Delias, A., Moch, H., Schultheiss, E., Feichter, G., Almendral, A. C., Gudat, F., and Torhorst, J. Angiogenesis in cervical neoplasia: microvessel quantitation in precancerous lesions and invasive carcinomas with clinicopathological correlations. Gynecol. Oncol., 67: 27-33, 1997.
10. Dellas, A., Schultheiss, E., Almendral, A. C., Gudat, F., Oberholzer, M., Feichter, G., Moch, H., and Torhorst, J. Altered expression of mdm-2 and its association with p53 protein status, tumor-cell-proliferation rate and prognosis in cervical neoplasia. Int. J. Cancer, 74: 421-425, 1997.
11. Kip1, cyclin E and C-myc expression with progression and prognosis in HPV-positive cervical neoplasms. Anticancer Res., 18: 3991-3998, 1998.
12. Moch, H., Presti, J. C., Jr., Sauter, G., Buchholz, N., Jordan, P., Mihalsch, M. J., and Waldman, F. M. Genetic aberrations detected by comparative genomic hybridization are associated with clinical outcome in renal cell carcinoma. Cancer Res., 56: 27-30, 1996.
13. Richter, J., Jiang, F., Gorog, J. P., Sartorius, G., Egenter, C., Gasser, T. C., Moch, H., Mihatsch, M. J., and Sauter, G. Marked genetic differences between stage pTa and stage pT1 papillary bladder cancer detected by comparative genomic hybridization. Cancer Res., 57: 2860-2864, 1997.
14. Jiang, F., Richter, J., Schraml, P., Bubendorf, L., Gasser, T., Sauter, G., Mihatsch, M. J., and Moch, H. Chromosomal imbalances in papillary renal cell carcinoma: genetic differences between histological subtypes. Am. J. Pathol., 153: 1467-1473, 1998.
15. Kallioniemi, O. P., Kallioniemi, A., Piper, J., Isola, I., Waldman, F. M., Gray, J. W., and Pinkel, D. Optimizing comparative genomic hybridization for analysis of DNA sequence copy number changes in solid tumors. Genes Chromosomes Cancer, 10: 231-243, 1994.
16. Kononen, J., Bubendorf, L., Kallioniemi, A., Barlund, M., Schraml, P., Leighton, S., Torhorst, J., Mihatsch, M. J., Sauter, G., and Kallioniemi, O. P. Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat. Med., 4: 844-847, 1998.
17. Bubendorf, L., Kononen, J., Koivisto, P., Schraml, P., Moch, H., Gasser, T. C., Willi, N., Mihatsch, M. J., Sauter, G., and Kallioniemi, O. P. Survey of gene amplifications during prostate cancer progression by high-throughout fluorescence in situ hybridization on tissue microarrays. Cancer Res., 59: 803-806, 1999.
18. Isola, J. J., Kallioniemi, O. P., Chu, L. W., Fuqua, S. A., Hilsenbeck, S. G., Osborne, C. K., and Waldman, F. M. Genetic aberrations detected by comparative genomic hybridization predict outcome in node-negative breast cancer. Am. J. Pathol., 147: 905-911, 1995.
19. Larson, A. A., Liao, S. Y., Stanbridge, E. J., Cavenee, W. K., and Hampton, G. M. Genetic alterations accumulate during cervical tumorigenesis and indicate a common origin for multifocal lesions. Cancer Res., 57: 4171-4176, 1997.
20. Cavenee, W. K., and White, R. L. The genetic basis of cancer. Sci. Am., 272: 72-79, 1995.
21. Fearon, E. R., Cho, K. R., Nigro, J. M., Kem, S. E., Simons, J. W., Ruppert, J. M., Hamilton, S. R., Preisinger, A. C., Thomas, G., Kinzler, K. W., and Vogelstein, B. Identification of a chromosome 18q gene that is altered in colorectal cancers. Science (Washington DC), 247: 49-56, 1990.
22. Hahn, S. A., Schutte, M., Hoque, A. T., Moskaluk, C. A., da Costa, L. T., Rozenblum, E., Weinstein, C. L., Fischer, A., Yeo, C. J., Hruban, R. H., and Kern, S. E. DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1. Science (Washington DC), 271: 350-353, 1996.
23. Eppert, K., Scherer, S. W., Ozcelik, H., Pirone, R., Hoodless, P., Kim, H., Tsui, L. C., Bapat, B., Gallinger, S., Andrulis, I. L., Thomsen, G. H., Wrana, J. L., and Attisano, L. MADR2 maps to 18q21 and encodes a TGFβ-regulated MAD-related protein that is functionally mutated in colorectal carcinoma. Cell, 86: 543-552, 1996.
24. Klingelhutz, A. J., Smith, P. P., Garrett, L. R., and McDougall, J. K. Alteration of the DCC tumor-suppressor gene in tumorigenic HPV-18 immortalized human keratinocytes transformed by nitrosomethylurea. Oncogene, 8: 95-99, 1993.
25. Klingelhutz, A. J., Hedrick, L., Cho, K. R., and McDougall, J. K. The DCC gene suppresses the malignant phenotype of transformed human epithelial cells. Oncogene, 10: 1581-1586, 1995.
26. Seizinger, B. R., Klinger, H. P., Junien, C., Nakamura, Y., LeBeau, M. M., Cavenee, W., Emanuel, B., Ponder, B., Naylor, S., Mitelman, F., Louis, D., Menon, A., Newsham, I., Decker, J., Kaelbling, M., Henry, I., and Deimling, A. V. Report of the committee on chromosome and gene loss in human neoplasia. Cytogenet. Cell Genet., 58: 1080-1096, 1991.
27. Mullokandov, M. R., Kholodilov, N. G., Atkin, N. B., Burk, R. D., Johnson, A. B., and Klinger, H. P. Genomic alterations in cervical carcinoma: losses of chromosome heterozygosity and human papilloma virus tumor status. Cancer Res., 56: 197-205, 1996.
28. Smits, P. H., Smits, H. L., Jebbink, M. F., and ter Schegget, J. The short arm of chromosome 11 likely is involved in the regulation of the human papillomavirus type 16 early enhancer-promoter and in the suppression of the transforming activity of the viral DNA. Virology, 176: 158-165, 1990.
29. Puig, S., Ruiz, A., Lazaro, C., Castel, T., Lynch, M., Palou, J., Vilalta, A., Weissenbach, J., Mascara, J. M., and Estivill, X. Chromosome 9p deletions in cutaneous malignant melanoma tumors: the minimal deleted region involves markers outside the p16 (CDKN2) gene. Am. J. Hum. Genet., 57: 395-402, 1995.
30. Jagasia, A. A., Block, J. A., Qureshi, A., Diaz, M. O., Nobori, T., Gitelis, S., and Iyer, A. P. Chromosome 9 related aberrations and deletions of the CDKN2 and MTS2 putative tumor suppressor genes in human chondrosarcomas. Cancer Lett., 105: 91-103, 1996.
31. Scheffner, M., Münger, K., Byrne, J. C., and Howley, P. M. The state of the p53 and retinoblastoma genes in human cervical carcinoma cell lines. Proc. Natl. Acad. Sci. USA, 88: 5523-5527, 1991.
32. Mitra, A. B., Murty, V. V., Pratap, M., Sodhani, P., and Chaganti, R. S. ERBB2 (HER2/neu) oncogene is frequently amplified in squamous cell carcinoma of the uterine cervix. Cancer Res., 54: 637-639, 1994.
33. Ndubisi, B., Sanz, S., Lu, L., Podczaski, E., Benrubi, G., and Masood, S. The prognostic value of HER-2/neu oncogene in cervical cancer. Ann. Clin. Lab. Sci., 27: 396-401, 1997.